NASDAQ: ACHVAchieve Life Sciences Inc Stock
$5.20+0.00 (+0%)
Updated Feb 6, 2023
ACHV Price
$5.20
Fair Value Price
$10.50
Market Cap
$50.50M
52 Week Low
$2.00
52 Week High
$8.13
P/E
-1.33x
P/B
48.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
21.72
Operating Cash Flow
-$32M
Beta
0.78
Next Earnings
Mar 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ACHV Overview
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACHV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACHV ($5.20) is undervalued by 50.47% relative to our estimate of its Fair Value price of $10.50 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACHV ($5.20) is significantly undervalued by 50.47% relative to our estimate of its Fair Value price of $10.50 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACHV due diligence checks available for Premium users.
Be the first to know about important ACHV news, forecast changes, insider trades & much more!
ACHV News
Valuation
ACHV fair value
Fair Value of ACHV stock based on Discounted Cash Flow (DCF)
Price
$5.20
Fair Value
$10.50
Undervalued by
50.47%
ACHV ($5.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACHV ($5.20) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACHV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.33x
Industry
11.5x
Market
14.99x
ACHV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
48.37x
Industry
5.06x
ACHV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACHV's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.1M
Profit Margin
0%
ACHV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$23.7M
Liabilities
$22.7M
Debt to equity
21.72
ACHV's short-term assets ($20.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACHV's short-term assets ($20.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACHV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACHV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.3M
Investing
$0.0
Financing
$126.0k
ACHV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACHV vs Biotech Stocks
Achieve Life Sciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.